Introduction
Female sexual function is a complex issue. Diminished arousal/desire, perceived or absent orgasm can be the result of many environmental and cultural factors, personal and relationship distress being an important cause making it difficult to identify clinical trial end points in the development of drugs while maintaining safety and efficacy. The FDA has provided us with a recent document clarifying some issues while leaving more questions. Industry and investigators are reminded of the importance of dialog with the regulatory authorities before initiating clinical studies.
Concepts regarding female sexual function
The New York Times Science Section 1 highlights 'Desire' and suggests that, in fact, we know very little about this motivation that pushes human life forward. The continuation of our population depends on sexuality. Since the initiation of industry interest in finding a magic pill, the possibilities look more like a Band-Aid. 2, 3 What is the repairable and marketable essence that we are seeking? Will it be both safe and effective? When Adam and Eve fell into sin they became conscious of new and selfish impulses over which they had no control. It was a matter simply of utilizing the mechanical equipment designed by the 'creator' to fulfill with deliberation, and a kind of grave appreciation, the requirements of the reproductive process. Lust and sex were integral to sin and celibacy was to be the badge of moral authority. 4 Today, we believe that normal sexual function for a woman is a complex quilted tapestry. Diminished arousal/desire, perceived or absent orgasm can be the result of many environmental and cultural factors, personal and relationship distress being an important cause. The act of sex includes her sexual self and self-image, intimate relationships, family, society and culture. Emotional intimacy may be the important underpinning. The complexities of environment, sexual and partner history, past abusive relationships, current medical problems and hormonal status all play a role. It has yet to be clearly determined what are the intricate neuroendocrine pathways. 5, 6 All of this makes it difficult for either regulatory agencies or pharmaceutical companies to find the magic marketable answer.
Several documents help us understand the complexity of female sexual function. These include two consensus documents 7, 8 and the Proceedings of the 2nd International Consultation on Sexual Function. 9 Both physical and emotional feedback is known to play crucial roles. 8 This starts with the stimuli from the external environment and the emotional experience of arousal and feeds into the central nervous system, for example, the paralimbic areas or central nervous system and the appropriate spinal cord receptors. This may include important sexual centers such as the medial preoptic area of the hypothalamus and other limbic and paralimbic structures. This intricate hormonal neurophysiological system would appear to be crucial. Arousal may in fact initiate desire.
What are the regulatory issues?
It is difficult for any regulatory agency to clarify appropriate clinical trial end points and the FDA should be commended for the attempt. The first Draft Guidance to Industry 10 was an initial attempt to communicate their thoughts to industry. It should be remembered that these guidance documents, publications and speeches are an attempt to share with the world the current thoughts on a subject and initiate feedback. These documents are not binding as a Federal Register Notice. FDA has a long history of challenges to women's health; many regulatory changes were the result of challenges to a woman's safety. 11 Patent medicines pre-1906 were targeted to female weakness; diethylstilbestrol and thalidomide all played important roles in strengthening the agency's regulatory oversight. In the end, safety and efficacy for any marketed drug or device is crucial.
Sexual difficulties are common among mature adults throughout the world. A number of epidemiology studies have pointed out the prevalence of female sexual problems. Data suggest that of 33% of women reported reduced sexual interest, 43% considered this to be a problem and of those, 87% reported sexual dissatisfaction (Laumann et al, 1999) . Sexual problems tend to be more associated with physical health and aging among men than women.
12-15 When lubrication is absent or there is sexual pain, over 50% find this a problem causing sexual dissatisfaction. 9 Another representative community study confirmed more than 50% of women wanted professional help for the sexual problems self-disclosed in 41% of them. 8 A woman's sexual function may be largely related to contextual factors-evidence of something psychologically or biologically amiss within the woman herself, being absent. Her sexual 'dysfunction' is logical and adaptive. Predisposing factors in the woman's past affecting her psychosexual development, for example, past abuse. Precipitating and perpetuating factors in the current context which are disrupting to, and/or consequences of her sexual difficulties, normal female sexual function would appear to be a prime example of the mandatory blending of mind and body.
Since the beginning of this discussion at the first Cape Cod Conference, there have been numerous discussions and documents from experts in the field. 2, 9 The measurement of defined end points often separates the clinical scientists from the regulatory specialists. The first attempt to share regulatory requirements from the FDA came in May 2000 'Guidance to Industry: Female Sexual Dysfunction-Clinical Development of Drug Products for Treatment'. 10 Many were disappointed to find that the following clinical trial end points were thought to be necessary: 'Satisfactory sexual intercourse, Sexual intercourse resulting in orgasm, Oral sex resulting in orgasm, and partner-mediated or selfmasturbation resulting in orgasm'. Orgasm appeared to be essential at every turning point. Fortunately, we were offered a thoughtful and scientific response to the agency's guidance paper by Althof et al. 16 This paper noted 'defining and measuring Female Sexual Dysfunction (FSD) is a complex and challenging task. Several factors have confounded the theory and measurement of FSD including: the use of an inappropriate male paradigm; difficulty in capturing the complexity of women's sexual response; an evolving but presently untested nosology; and the relative independence between subjective and objective aspects of women's sexual response.' In a Viagra world we seemed to be in a strange new culture. Just who in the couple was in control and defines satisfactory sexual intercourse?
This 2000 document was the first to identify the importance of patient response outcomes (PROs) known as scales or questionnaires, although the Agency was using them in many other clinical trials and has recently updated a PRO draft guidance. 17 It is unfortunate the Agency believed that wellvalidated PROs to be less sensitive end points than perceived orgasms. The accepted surrogate end point of a clinical trial is a laboratory measurement or a physical sign used as a substitute for a clinically meaningful end point that measures directly how a patient feels, functions, or survives. 18 Changes induced by therapy on the surrogate end point are expected to reflect changes in a clinically meaningful end point and a validated surrogate marker is a clinical measurement statistically associated with a clinical outcome. Many surrogate end points accepted by the Agency, for example, blood pressure, tumor response, testosterone, or blood glucose may be less sensitive and specific than a wellvalidated PRO. [19] [20] [21] The recent paper 22 clarifies Agency thinking and demonstrates considerations leaving more questions than answers. Much of this article appears to reiterate the 2004 Advisory Committee meeting regarding the female testosterone patch. 23 The testosterone pathway has been fraught with its unique difficulties. Several important papers have provided us scientific thoughts on this subject. [24] [25] [26] [27] No population-based study has identified a testosterone-deficiency disease associated with hormonal levels. Many believe that the fulfillment of sexual desire based on androgens is an uncommon reason/ incentive for sexual activity for many women and, in fact, sexual desire is frequently experienced only after sexual stimuli have elicited subjective sexual arousal. 9 The measurement of testosterone in most laboratories is often less than accurate. 28 Not only has a testosterone-deficiency disease not been characterized, but also the identification of this disease would be more difficult with the current analytical specificity and precision. 28 However, testosterone for some women, whether physiologic or pharmacologic appears to improve sexual response and the anticipation of clinical trials lasting Regulatory issues in FSD JL Fourcroy 5-7 years does not seem to be an acceptable and logical approach. Whether any trial will be large or long enough to assess the long-term risk of cardiovascular events and breast cancer is unclear. One wonders if other pathways will be held to the same high standard. The cardiovascular events and breast cancer risks appear to be important determinants. 22 The European Union approach has been to define narrowly the intended use for the testosterone patch, the product is indicated for the treatment of hypoactive sexual desire disorder in bilaterally oophorectomized and hysterectomized (surgically induced menopause) women receiving concomitant estrogen therapy. This ignores the complexities and uncertainties of hormone therapy in women. 29, 30 Summary The Agency has made an important step in opening the dialog between industry regulatory authorities while reminding us of the importance of dialog before planning clinical trials. It will be important to define with the Agency acceptable event end point(s) other than orgasm, which is no longer a necessary component of a satisfactory sexual event. The relationship of many factors melds the final product for a woman. A woman's sexuality is very contextual-a very rich and complex tapestry. We agree with the important emphasis on safety and efficacy and dialog but wonder if we should not be looking at shorter pathways for our women. However, we concur with recent reports emphasizing the importance of safety concerns for all marketed products. 31, 32 
